LHFPL2

Across TCGA pan-cancer cohorts, LHFPL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LHFPL2 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LHFPL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LHFPL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where LHFPL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.337	0.844	.006	24	view →
GBM	OS	Median	All	0.287	0.492	.013	2	view →
CCRCC	OS	Median	All	0.770	1.000	.027	2	view →
LUAD	OS	Median	II,III,IV	0.942	0.507	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LHFPL2–PDAC (DFS)

Open the PDAC breakdown →